The Platelet-Oriented Inhibition in New TIA (POINT) Trial (2015-2016)

You are here

Funded by the National Institutes of Health

Funding Years: 2015-2016

POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel 75mg/day (after a loading dose of 600mg) is effective in improving survival free from major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours time last known free of new ischemic symptoms of TIA or minor ischemic stroke in subjects receiving aspirin 50-325mg/day.

PI(s): Claiborne Johnston

Co-I(s):  J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon Poisson, Yuko Palesch